ArticleInternational journal of environmental research and public health2021
A Cost-Benefit Analysis of the COVID-19 Asymptomatic Mass Testing Strategy in the North Metropolitan Area of Barcelona.
Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Economic evaluation of laboratory diagnostic test types in Covid-19 epidemic: A systematic review.International journal of surgery (London, England) · 2022Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- Impact ofFrontiers in public health · 2026Article
- Article
- A Cross-Sectional Study of the Use of Antigen Rapid Diagnostic Tests for Community Identification of SARS-CoV-2 in Kenya.The American journal of tropical medicine and hygiene · 2025Article
- Assessing SARS-CoV-2 Testing Adherence in a University Town: Recurrent Event Modeling Analysis.JMIR public health and surveillance · 2024Article
- Lay beliefs of COVID-19 vaccine refusal among intercity commercial drivers in the Volta region of Ghana: recommendations for improved vaccine uptake.Tropical diseases, travel medicine and vaccines · 2024Article
- Exploring machine learning algorithms for predicting fertility preferences among reproductive age women in Nigeria.Frontiers in digital health · 2024Article
- Assessment of a SARS-CoV-2 population-wide rapid antigen testing in Italy: a modeling and economic analysis study.European journal of public health · 2023Article
- Economic evaluation of strategies against coronavirus: a systematic review.Health economics review · 2023Review
- A Strategy Formulation Framework for Efficient Screening during the Early Stage of a Pandemic.Tropical medicine and infectious disease · 2023Article
- Effect of Nucleic Acid Screening Measures on COVID-19 Transmission in Cities of Different Scales and Assessment of Related Testing Resource Demands-Evidence from China.International journal of environmental research and public health · 2022Article
- COVID-19 Rapid Antigen Tests: Bibliometric Analysis of the Scientific Literature.International journal of environmental research and public health · 2022Article
- Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: a modelling and economic analysis study.BMC health services research · 2022Article
- Perception of COVID-19 Testing in the Entire Population.Frontiers in public health · 2022Article
- Development of a risk assessment profile tool to determine appropriate use of SARS-CoV-2 rapid antigen detection tests for different activities and events in Ireland, since October 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Article
- The Role of SARS-CoV-2 Testing on Hospitalizations in California.Life (Basel, Switzerland) · 2021Article
- Impact of Mass Workplace COVID-19 Rapid Testing on Health and Healthcare Resource Savings.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe epidemiological situation generated by COVID-19 has highlighted the importance of applying non-pharmacological measures in the management of the epidemic. Mass screening of the asymptomatic general population has been established as a priority strategy by carrying out diagnostic tests to detect possible cases, isolate contacts, cut transmission chains and thus limit the spread of the virus.
objectiveTo evaluate the economic impact of mass COVID-19 screenings of an asymptomatic population during the first and second wave of the epidemic in Catalonia, Spain. METHODOLOGY: Cost-Benefit Analysis based on the estimated total costs of mass screening versus health gains and associated health costs avoided.
resultsExcluding the value of monetized health, the Benefit-Cost ratio was estimated at 0.45, a low value that would seem to advise against mass screening policies. However, if monetized health is included, the ratio is close to 1.20, reversing the interpretation. In other words, the monetization of health is the critical element that tips the scales in favour of the desirability of screening. Results show that the interventions with the highest return are those that maximize the percentage of positives detected.
conclusionEfficient management of resources for the policy of mass screening in asymptomatic populations can generate high social returns. The positivity rate critically determines its desirability. Likewise, precocity in the detection of cases will cut more transmissions in the chain of contagion and increase the economic return of these interventions. Maximizing the value of resources depends on screening strategies being accompanied by contact-tracing and specific in their focus, targeting, for example, high-risk subpopulations with the highest rate of expected positives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.